Clinical Trial: Treatment of Hidradenitis Suppurativa Using Etanercept
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Treatment of Hidradenitis Suppirativa With Etanercept Injection
Brief Summary: Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.
Detailed Summary:
Sponsor: Penn State University
Current Primary Outcome: Physician global assessment of HS of clear or mild at week 12 [ Time Frame: Week 12 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Penn State University
Dates:
Date Received: July 29, 2009
Date Started: April 2005
Date Completion:
Last Updated: July 29, 2009
Last Verified: July 2009